Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10586437 | 0.86 | TDP1 (0.48) | TDP1RECQLERN1S100A4IDO1 | |
| SCHEMBL6930919 | 0.85 | TDP1 (0.55) | TDP1ERN1S100A4TSHRSMN1; SMN2 | |
| SCHEMBL6571919 | 0.82 | ALDH1A1 (0.46) | TDP1RECQLS100A4CYP3A4TSHR | |
| SCHEMBL10041658 | 0.82 | TDP1 (0.52) | TDP1ERN1S100A4ALDH1A1KMT2A | |
| SCHEMBL6003472 | 0.82 | ERN1 (0.52) | TDP1ERN1S100A4TSHRALDH1A1 | |
| SCHEMBL27547924 | 0.81 | ERN1 (0.47) | TDP1ERN1S100A4KMT2AMEN1 | |
| SCHEMBL13350048 | 0.79 | ERN1 (0.59) | TDP1ERN1S100A4CYP3A4SMN1; SMN2 | |
| SCHEMBL2471502 | 0.79 | ALDH1A1 (0.47) | TDP1ERN1S100A4IDO1CYP3A4 | |
| SCHEMBL3589058 | 0.79 | PTPRC (0.42) | TDP1ERN1IDO1ALDH1A1KMT2A | |
| SCHEMBL31488266 | 0.79 | ERN1 (0.59) | TDP1ERN1S100A4CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088888-A | Preparation method of alprazolam and impurity LAP thereof | 山东安信制药有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-8642808-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-10-20 | — | — | US | disclosed |
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| EP-2007741-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | Xytis Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | disclosed |
| WO-2007109288-A2 | ENANTIOMERICALLY PURE R-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109289-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | TDP1 4494/4885RECQL 4241/4885ERN1 4121/4885 |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, CYP2C9, CYP3A5 | TDP1 1105/4885RECQL 747/4885ERN1 565/4885 |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | TDP1 4494/4885RECQL 4241/4885ERN1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.